BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhao H, Yang Q, Hu Y, Zhang J. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells. Oncol Rep 2018;40:3223-34. [PMID: 30272286 DOI: 10.3892/or.2018.6716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Lu F, Hou Y, Chen Z, Jiang J, He X, Xia Y, Cao K, Chang L, Li W. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Technol Cancer Res Treat 2021;20:15330338211016369. [PMID: 33977814 DOI: 10.1177/15330338211016369] [Reference Citation Analysis]
3 Manjunath M, Choudhary B. Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett 2021;22:512. [PMID: 33986872 DOI: 10.3892/ol.2021.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M. Emerging ways to treat breast cancer: will promises be met? Cell Oncol (Dordr) 2018;41:605-21. [PMID: 30259416 DOI: 10.1007/s13402-018-0409-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
5 Furlanetto J, Loibl S. Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. Breast Care (Basel) 2020;15:217-26. [PMID: 32774215 DOI: 10.1159/000508759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wawruszak A, Luszczki JJ, Kalafut J, Okla K, Halasa M, Rivero-Muller A, Stepulak A. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis. Int J Mol Sci 2019;20:E3663. [PMID: 31357442 DOI: 10.3390/ijms20153663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
7 Wawruszak A, Luszczki J, Halasa M, Okon E, Landor S, Sahlgren C, Rivero-Muller A, Stepulak A. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together. Int J Mol Sci 2021;22:5184. [PMID: 34068438 DOI: 10.3390/ijms22105184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Yang L, Qin X, Liu H, Wei Y, Zhu H, Jiang M. Design, synthesis and biological evaluation of a series of new resveratrol analogues as potential anti-cancer agents. R Soc Open Sci 2019;6:190125. [PMID: 31598278 DOI: 10.1098/rsos.190125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]